Clinical trials: Non-Resectable Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma
- Trial name
- NCT06909708
- Testing
- SIRT, cTACE
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
This Phase I/II trial will evaluate the safety and activity of chemo-radiotherapy comprising a regimen of Sorafenib chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), for…
- Trial name
- NCT00712790
- Testing
- Sorafenib, SIR-Spheres
- Where
- 5 sites in Burma, Malaysia and 2 more
- Volunteers
- 35 people
- Sponsor
- Singapore Clinical Research Institute
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00128596
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable…
- Trial name
- PhotonAB (NCT06339424)
- Testing
- Atezolizumab, Bevacizumab, Photon radiotherapy
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC)…
- Trial name
- Kirros (NCT06096779)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Genentech, Inc.
HCC - Hepatocellular Carcinoma
Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Unresectable hepatocellular carcinoma (uHCC) constitutes a significant health burden in the Asia-Pacific (APAC) region, particularly in China, where it is frequently associated with hepatitis B virus (HBV) infection and diagnosed…
- Trial name
- NCT07109336
- Testing
- Heterogeneous Treatment Effect-Based Decision Model
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.
Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.
- Trial name
- NCT07664007
- Testing
- Eicosapentaenoic acid oral lipidic emulsion, Pacebo oral lipidic emulsion
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Liver Cancer
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00941967
- Testing
- gemcitabine hydrochloride, oxaliplatin, sorafenib tosylate
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
Hepatocellular Carcinoma
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment…
- Trial name
- NCT06406634
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Cancer Hospital
Unresectable Hepatocellular Carcinoma
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- TACE (NCT02006030)
- Testing
- ADI-PEG 20, Transarterial chemoembolization
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Polaris Group
Hepatocellular Carcinoma
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT05003700
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Carcinoma, Hepatocellular
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Vast majority of patients with hepatocellular carcinoma (HCC) present with unresectable disease. In the last decade results of randomized trials and a subsequent metaanalyses established transarterial chemoembolization (TACE) or…
- Trial name
- TACE-SBRT (NCT02794337)
- Testing
- SBRT, TACE, Sorafenib
- Where
- 2 sites in India
- Volunteers
- 67 people
- Sponsor
- Tata Memorial Hospital
Hepatocellular Carcinoma
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT05432492
- Testing
- AK112
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Akeso
Hepatocellular Carcinoma, Esophagogastric Varices
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma
The study is aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with endoscopic therapy for unresectable hepatocellular carcinoma (HCC) complicated with esophagogastric varices (EGV) and seek out…
- Trial name
- NCT05017922
- Testing
- transarterial chemoembolization combined with endoscopic therapy
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Qilu Hospital of Shandong University
Hepatocellular Carcinoma
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.
- Trial name
- NCT04541173
- Testing
- Y-90 TARE, Atezolizumab, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Aiwu Ruth He, MD
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Carcinoma, Hepatocellular
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Nexavar for unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT01411436
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 1,637 people
- Sponsor
- Bayer